Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | TYR | P14679 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | USP5 | P45974 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2186334 | 0.82 | PTGS2 (0.53) | ALDH1A1MAPK1TDP1CYP2C9LMNA | |
| SCHEMBL4902698 | 0.81 | ALDH5A1 (0.57) | ALDH1A1MAPK1TDP1TYRCYP2C9 | |
| SCHEMBL222221 | 0.81 | ALDH1A1 (0.74) | ALDH1A1MAPK1TDP1HTTLMNA | |
| SCHEMBL21600628 | 0.79 | HDAC4 (0.51) | ALDH1A1MAPK1TDP1TYRCYP2C9 | |
| SCHEMBL8844786 | 0.79 | CYP2C9 (0.47) | ALDH1A1MAPK1TYRCYP2C9USP5 | |
| Water SCHEMBL11592745 | 0.78 | ALDH1A1 (0.70) | ALDH1A1MAPK1TDP1HTTLMNA | |
| Water SCHEMBL11592742 | 0.78 | ALDH1A1 (0.70) | ALDH1A1MAPK1TDP1HTTLMNA | |
| SCHEMBL7821842 | 0.78 | ALDH1A1 (0.63) | ALDH1A1MAPK1TDP1CYP2C9HTT | |
| SCHEMBL7821843 | 0.78 | ALDH1A1 (0.63) | ALDH1A1MAPK1TDP1CYP2C9HTT | |
| SCHEMBL5373801 | 0.77 | TYR (0.48) | ALDH1A1MAPK1TYRCYP2C9USP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636192-B9 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL IND LTD (JP) | 2015-07-01 | — | — | EP | disclosed |
| US-20140051857-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2014-02-20 | — | — | US | disclosed |
| EP-1636192-B1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL IND LTD (JP) | 2014-01-15 | — | — | EP | disclosed |
| US-20130012708-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2013-01-10 | — | — | US | disclosed |
| US-8318796-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-20110077290-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20100166765-A1 | BENZOQUINAZOLINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | disclosed |
| US-7695863-B2 | rechargeable batteries having excellent battery cycle properties, electrical capacity and storage characteristic during charging, comprising electrodes and a nonaqueous electrolytic solution containing a dicarbonyl compound as an additive | UBE INDUSTRIES, LTD. (JP) | 2010-04-13 | — | — | US | disclosed |
| EP-1917246-B1 | BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS | NOVARTIS AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-7576115-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| EP-1917246-A1 | BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS | Novartis AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| US-20080102377-A1 | rechargeable batteries having excellent battery cycle properties, electrical capacity and storage characteristic during charging, comprising electrodes and a nonaqueous electrolytic solution containing a dicarbonyl compound as an additive | UBE INDUSTRIES, LTD (JP) | 2008-05-01 | — | — | US | disclosed |
| US-7351841-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-04-01 | — | — | US | disclosed |
| US-20080027068-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
| WO-2007020046-A1 | BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS | NOVARTIS AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077290-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | ALDH1A1 3234/4885MAPK1 950/4885TDP1 4730/4885 |
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NR2C2, ROR1, NR0B2 | ALDH1A1 3160/4885MAPK1 895/4885TDP1 4740/4885 |
| US-20080027068-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | ALDH1A1 3206/4885MAPK1 995/4885TDP1 4716/4885 |
| US-20140051857-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | ALDH1A1 3234/4885MAPK1 950/4885TDP1 4730/4885 |
| US-20100166765-A1 | BENZOQUINAZOLINE DERIVATIVES | CACNA1A, BMP4, TPX2 | ALDH1A1 3966/4885MAPK1 1902/4885TDP1 2316/4885 |
| US-20130012708-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | ALDH1A1 3234/4885MAPK1 950/4885TDP1 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.